Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)
Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –
Zevra Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Zevra Therapeutics's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $61.93M, up 4.1% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.93M | +4.1% |
| FY2024 | Dec 31, 2024 | $59.50M | +1074.6% |
| FY2023 | Dec 31, 2023 | $5.07M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $61.93M | +4.1% |
| Q3 FY2025 | Sep 30, 2025 | $61.31M | +4.1% |
| Q2 FY2025 | Jun 30, 2025 | $60.69M | +4.1% |
| Q1 FY2025 | Mar 31, 2025 | $60.09M | +1087.8% |
| Q4 FY2024 | Dec 31, 2024 | $59.50M | +1074.6% |
| Q3 FY2024 | Sep 30, 2024 | $58.90M | +1061.1% |
| Q2 FY2024 | Jun 30, 2024 | $58.33M | – |
| Q1 FY2024 | Mar 31, 2024 | $5.06M | +547.8% |
| Q4 FY2023 | Dec 31, 2023 | $5.07M | +548.7% |
| Q3 FY2023 | Sep 30, 2023 | $5.07M | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $781.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $781.00K | – |
See a number that looks wrong?